Development of Novel Clinical Endpoints in Intermediate AMD

Summary

Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD) - MACUSTAR

Conditions

• Age Related Macular Degeneration (AMD)

Interventions

OTHER

No intervention

According to clinical practice.

Sponsors & Collaborators

• Bayer

  collaborator INDUSTRY

• Moorfields Eye Hospital NHS Foundation Trust

  collaborator OTHER

• Novartis Pharmaceuticals

  collaborator INDUSTRY

• Association for Innovation and Biomedical Research on Light and Image

  collaborator OTHER

• City, University of London

  collaborator OTHER

• European Clinical Research Infrastructure Network

  collaborator OTHER

• La Fondation Voir et Entendre

  collaborator UNKNOWN

• Hoffmann-La Roche

  collaborator INDUSTRY

• Radboud University Medical Center

  collaborator OTHER

• University of Sheffield

  collaborator OTHER

• University College, London

  collaborator OTHER

• Carl Zeiss Meditec AG

  collaborator INDUSTRY

• Innovative Medicines Initiative

  collaborator OTHER

• Frank G. Holz

  lead OTHER

Principal Investigators

• Frank Holz, Prof. Dr. med. · University Hospital, Bonn

Eligibility

Min Age

55 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2018-03-26

Primary Completion

2026-02-28

Completion

2026-02-28

Countries

• Denmark
• France
• Germany
• Italy
• Netherlands
• Portugal
• United Kingdom

Study Locations